Patent US5512294 - Targeted polymerized liposome contrast agents - Google Patents
The polymerized imaging enhancement liposome particles interact with receptor targets holding the image enhancement agent to ... Polymerized liposome particles based upon lipids having a polymerizable functional group and a metal chelator to attach an ... imaging enhancement agent and lipids having an active targeting group to provide targeted polymerized liposome contrast agents ... 1. A polymerized liposome image contrast agent composition consisting essentially of: liposome forming lipids, said liposome ...http://www.google.com/patents/US5512294?dq=6,370,566
US5143713A - 99m Tc labeled liposomes - Google Patents
... a 99m Tc carrier is used to label preformed liposomes or liposome-encapsulated hemoglobin. 99m Tc-labeled liposomes and ... A kit method useful for the convenient preparation of 99m Tc-labeled liposomes or liposome-encapsulated hemoglobin for clinical ... The invention also relates to a method of labeling neutrophils using 99m technetium-labeled liposomes or liposome-encapsulated ... liposome-encapsulated 99m Tc labeled hemoglobin are highly stable in vitro and in vivo and are suitable for a variety of ...https://patents.google.com/patent/US5143713A/en
Patent US4483921 - Immunoassay with antigen or antibody labeled liposomes sequestering enzyme - Google Patents
... complement acting to release the enzyme if an immunospecific antigen-antibody complex is formed at the surface of the liposome ... enzyme encapsulating liposomes which are immunospecifically ruptured in the presence of cognate antibody and active complement ... 2. A liposome in accordance with the liposome of claim 1, wherein said liposome is formed of a lipid which is a member of the ... Preferably the liposome is carried in a liquid media and is stable for a period of at least 60 days. Preferably the liposome ...http://www.google.com/patents/US4483921?dq=6,952,563
Patent US6193998 - Method for producing liposomes with increased percent of compound encapsulated - Google Patents
... by use of a lipid having a carbon chain containing from about 13 to about 28 carbons during preparation of the liposomes. ... liposomes. . . in. . . the. . . final. . . product. Amt. .. . of. . . drug. . . in. . . final. . . product. ] ... Liposome Technology, Inc.. High-concentration liposome processing method. US4877619 *. Apr 6, 1987. Oct 31, 1989. Vestar, Inc. ... Liposome Technology, Inc.. High-encapsulation liposome processing method. US4769250. Oct 26, 1987. Sep 6, 1988. Vestar, Inc.. ...http://www.google.com/patents/US6193998?dq=3798360
Patent US5626870 - Method of forming hydrogel particles having a controlled size using liposomes - Google Patents
... encapsulating an effective amount of each of one or more hydrogel substances and one or more release agents in liposomes in a ... adding initiator to the liquid medium and into the liposomes, thereby initiating reaction of the one or more hydrogel ... substances, whereby hydrogel particles are formed in the liposomes, and d) removing any extra-liposomal initiator from the ... A method of fabricating hydrogel particles within liposomes, which entails: a) ...http://www.google.co.uk/patents/US5626870
US5674528A - Hemoglobin-encapsulated liposome - Google Patents
The hemoglobin-encapsulated liposome comprises a liposome and an enzymatically active hemoglobin solution encapsulated therein ... The thus supplemented hemoglobin solution encapsulated in the liposome exhibits an improved resistance to conversion to ... Therefore, the hemoglobin-encapsulated liposome of the present invention is useful as a blood substitute. ... A hemoglobin-encapsulated liposome is provided. The hemoglobin-encapsulated liposome comprises a liposome and an enzymatically ...https://patents.google.com/patent/US5674528A/en
Patent US4551288 - Processes for the preparation of liposome drug delivery systems - Google Patents
The column effluent is continuously monitored to detect the liposome fraction eluted, which is collected. The free medicament, ... Process and apparatus for the production of medicament containing liposomes, comprising an aliphatic lipid-sterol-water ... Apparatus for producing liposomes and method of producing liposomes. WO1988006442A1 *. Mar 3, 1988. Sep 7, 1988. The Liposome ... The Liposome Company, Inc.. Low toxicity drug-lipid systems. US5616341 *. Aug 26, 1993. Apr 1, 1997. The Liposome Company, Inc. ...http://www.google.com/patents/US4551288?dq=ininventor:oliver+ininventor:steele
US4605630A - Large-liposome agglutination reagent and method - Google Patents
The reagent is composed of liposomes predominantly in the 1 to 20 micron diameter size range. Each liposome has a surface array ... A dye in the liposomes allows such agglutination to be visualized easily without magnification. ... Thiol reactive liposomes US4483929A (en) * 1982-05-03. 1984-11-20. Liposome Technology Incorporated. Liposomes with glycolipid- ... Thiol reactive liposomes US4483929A (en) * 1982-05-03. 1984-11-20. Liposome Technology Incorporated. Liposomes with glycolipid- ...https://patents.google.com/patent/US4605630A/en
US6033708A - Method for producing sterile filterable liposome dispersion - Google Patents
A key step in the method of the present invention is the addition of a passivating protein prior to hydration of the liposomes ... The present invention relates to a composition and method of producing noggregating, filterable dispersion of liposome ... Liposome Technology, Inc.. Liposome/bronchodilator method & System US5589189A (en) * 1994-09-14. 1996-12-31. Nexstar ... Liposome Technology, Inc.. Liposome/bronchodilator method & System US5589189A (en) * 1994-09-14. 1996-12-31. Nexstar ...https://patents.google.com/patent/US6033708A/en
US5464629A - Method of forming hydrogel particles having a controlled size using liposomes - Google Patents
... adding initiator to the liquid medium and into the liposomes, thereby initiating reaction of the one or more hydrogel-forming ... which entails encapsulating an effective amount of one or more hydrogel-forming substances in liposomes in a liquid medium, ... A method of fabricating hydrogel particles of controlled size within liposomes is provided, ... These liposomes are reduced in size by extruding large liposomes named Multilamellar liposomes (MLVs) of about 0.8 μm pore ...https://patents.google.com/patent/US5464629?oq=4335110
US20060002992A1 - Atomizable liposomes and their use for the pulmonary administration of active substances - Google...
... to prepare liposomes that are stabile during nebulization with commercially available nebulizers and exhibit sustained release ... Liposome Technology, Inc.. Liposome/bronchodilator method & System US5380531A (en) * 1990-07-31. 1995-01-10. The Liposome ... Liposome Technology, Inc.. Liposome/bronchodilator method & System US5399331A (en) * 1985-06-26. 1995-03-21. The Liposome ... A61K9/1271-Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers ...https://patents.google.com/patent/US20060002992
Intranasal Immunization with DOTAP Cationic Liposomes Combined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and...
DOTAP/DC-chol liposomes also enhanced OVA uptake by CD11c+ dendritic cells in nasal-associated lymphoid tissue. These data ... Intranasal vaccination with ovalbumin (OVA) in combination with DOTAP/DC-chol liposomes induced the production of OVA-specific ... Additionally, nasal-associated lymphoid tissue and splenocytes from mice treated with OVA plus DOTAP/DC-chol liposome showed ... In this study, we show that intranasal administration of a cationic liposome composed of 1,2-dioleoyl-3-trimethylammonium- ...https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0139785
Vascular Shutdown and Pro-inflammatory Cytokine Expression in Breast Cancer Tumors after Photodynamic Therapy Mediated by Nano...
Cell culture and liposome preparation: Murine breast cancer cell line 4T1 was purchased from American Type Cell Collection. 4T1 ... Figure 1 describes a model of the liposome used in this article. The model represents the spherical nano-vesicles composed by a ... Figure 1: Liposome model containing the Aluminium-Chloride-Phthalocyanine (AlClPc) among the phospholipid bilayer (Section A); ... Breast cancer; Liposomes; Nanoparticles; Tumors; Cytokine Expression; Vascular shutdown. Introduction. Breast cancer is the ...https://www.omicsonline.org/open-access/vascular-shutdown-and-proinflammatory-cytokine-expression-in-breast-cancer-tumors-after-photodynamic-therapy-mediated-by-nanosized-liposomes-2157-7439-5-218.php?aid=30025
PLOS ONE: Immunization with a Hemagglutinin-Derived Synthetic Peptide Formulated with a CpG-DNA-Liposome Complex Induced...
Here, we formulated an efficacious peptide vaccine without carriers using phosphodiester CpG-DNA and a special liposome complex ... Immunization with a Hemagglutinin-Derived Synthetic Peptide Formulated with a CpG-DNA-Liposome Complex Induced Protection ...https://journals.plos.org/plosone/article/figure?id=10.1371/journal.pone.0048750.g005
31 P-NMR and Differential Scanning Calorimetry Studies for Determining Vesicleâ s Drug Physical State and Fraction in ...
Â s Drug Physical State and Fraction in Alendronate Liposomes. Eyal Afergan1, Yousef Najajreh2, Dikla Gutman1, Hila Epstein1, ... liposome system in order to predict their behavior and stability in-vitro and in-vivo . ... on theoretical calculations and DSC analysis it can be concluded that AL N is dissolved in the aqueous core of the liposome. ... Differential Scanning Calorimetry Studies for Determining Vesicle's Drug Physical State and Fraction in Alendronate Liposomes. ...https://www.omicsonline.org/peer-reviewed/31rnpnmr-and-differential-scanning-calorimetry-studies-for-determining-vesicles-drug-physical-state-and-fraction-in-rnalendronate-354.html
Effective, Broad Spectrum Control of Virulent Bacterial Infections Using Cationic DNA Liposome Complexes Combined with...
This compound is comprised of cationic liposome DNA complexes (CLDC) and crude membrane preparations (MPF) obtained from ...http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1000921
Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy
We demonstrate that the liposome-based vaccine elicited, rapidly and robustly, specific antisera in wild-type mice and in Tau. ... Here we adapted the liposome-based amyloid vaccine that proved safe and efficacious, and incorporated a synthetic ... The data corroborate the hypothesis that liposomes carrying phosphorylated peptides of protein Tau have considerable potential ...http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0072301
US6274115B1 - Method of targeting a specific location in a body using phospholipid and cholesterol liposomes which encapsulate...
A61K9/1271-Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers ... Liposome carriers in chemotherapy of leishmaniasis US4193983A (en) 1978-05-16. 1980-03-18. Syva Company. Labeled liposome ... Liposomes were annealed at 60° C. for 10 minutes and centrifuged at 300× g. Liposomes were separated from unencapsulated NTA ... One hour after the injection of the liposomes as discussed in the previous paragraph, 1 mg of the type of liposomes discussed ...https://patents.google.com/patent/US6274115
US20040034336A1 - Charged liposomes/micelles with encapsulted medical compounds - Google Patents
A charged liposome or micelle encapsulated therapeutic agent or medicament for the treatment of an obstruction in blood vessel ... to a configuration wherein the expansion member dilates the obstruction and the expansion member delivers the charged liposomes ... Liposome composition and its production US5043166A (en) * 1987-01-09. 1991-08-27. Hadasit Medical Research, Inc.. Liposome/ ... Liposome/doxorubicin composition and method US5043166A (en) * 1987-01-09. 1991-08-27. Hadasit Medical Research, Inc.. Liposome/ ...https://patents.google.com/patent/US20040034336A1/en
US5755788A - Prosthesis and implants having liposomes bound thereto and methods of preparation - Google Patents
Processes for making the prostheses and implants of the invention and for preparing the prostheses and implants for liposome ... Prostheses and implants are provided which have bound liposomes which are freeze-thaw and dehydration stable and which resist ... Liposome Company. Dehydrated liposomes US4880635A (en) * 1984-08-08. 1989-11-14. The Liposome Company, Inc.. Dehydrated ... The Liposome Company, Inc.. Dehydrated liposomes US4883665A (en) * 1985-04-11. 1989-11-28. Takeda Chemical Industries, Ltd.. ...https://patents.google.com/patent/US5755788A/en
"Lymphcoyte recognition of h-2 antigen in liposomes." by S H. Herrmann and M F. Mescher
Herrmann, S H. and Mescher, M F., "Lymphcoyte recognition of h-2 antigen in liposomes." (1981). Subject Strain Bibliography ...https://mouseion.jax.org/ssbb1981/2242/
"Immunogenic synergy of haptenated liposomes and haptenated hemocyanin " by H Snippe, A V. Houte et al.
Snippe, H; Houte, A V.; and Merchant, B, "Immunogenic synergy of haptenated liposomes and haptenated hemocyanin in b-cell ... Immunogenic synergy of haptenated liposomes and haptenated hemocyanin in b-cell defective cba/n mice. Abstr. ...https://mouseion.jax.org/ssbb1982/2073/
"Inhibition of PHA-induced lymphocyte stimulation by liposome incubatio" by John R. Carlson
Carlson, John R., "Inhibition of PHA-induced lymphocyte stimulation by liposome incubation." (1975). Summer and Academic Year ...https://mouseion.jax.org/strp/618/
"Analysis of the fate of systemically administered liposomes and implic" by G Poste, C Bucana et al.
Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. ... "Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery." (1982). Subject ...https://mouseion.jax.org/ssbb1982/3170/
Patent US8133500 - Compressed high density fibrous polymers suitable for implant - Google Patents
An embodiment of the present invention may be made by the following steps: providing a mixture comprising a plurality of fibers, a lubricant, and a suspension fluid, with the suspension fluid filling a void space between said fibers and subjecting said mixture to at least one compressive force. The compressive force causes the migration and alignment of said fibers; and may remove substantially all of the suspension fluid from said mixture. The mixture may further comprise a biologically active agent, or a reinforcing agent.http://www.google.com/patents/US8133500?dq=5319712